Partnerships

At CRISPR Therapeutics, partnerships form a core component of our strategy, allowing us to access capabilities and resources to support our therapeutic programs. We are interested in partnering with biopharma companies, academic centers, universities and other relevant organizations. For inquiries, please contact us at BD@crisprtx.com.

Major Strategic Partnerships

Vertex Logo

Read more

CRISPR Therapeutics established a four-year strategic research collaboration with Vertex Pharmaceuticals. The initial research focuses on discovering treatments to address the underlying genetic causes of cystic fibrosis and hemoglobinopathies, specifically sickle cell disease and β-thalassemia. Vertex and CRISPR will also evaluate a specified number of other genetic targets as part of the collaboration. For the hemoglobinopathy programs, Vertex and CRISPR will equally share all research and development costs and sales, with CRISPR Therapeutics leading commercialization efforts in the U.S. As part of the agreement, CRISPR received an up-front commitment of $105 million and is eligible to receive future development, regulatory and sales milestones, and royalties on future sales.

Casebia

Read more

CRISPR Therapeutics and Bayer formed Casebia Therapeutics to bring breakthrough therapies to patients suffering from serious conditions such as blood disorders, blindness and congenital heart disease. CRISPR brings its proprietary CRISPR/Cas9 gene-editing technology to Casebia, while Bayer brings protein engineering expertise and deep experience in the targeted disease areas. CRISPR has 50 percent ownership in Casebia, which is fueled by $300 million in research and development funding from Bayer over five years.

Viacyte

Read more

CRISPR Therapeutics established a five-year collaboration with ViaCyte, Inc. focused on the discovery, development, and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes. CRISPR and ViaCyte will jointly seek to develop an immune-evasive stem cell line as a first step on the path to an allogeneic stem-cell derived product. Upon successful completion of these studies and identification of a product candidate, the parties will jointly assume responsibility for further development and commercialization worldwide.

Delivery Technologies

Maxcyte Sized
Curevac Sized
Stridebio Sized
Mit Sized

Immuno-oncology

Neon Sized
Mgh Sized
Mastercell Sized

Exploratory

Fara Uab
Target Uf